摘要
目的:观察国产阿托伐他汀强化降脂治疗对冠心病高危患者的疗效和其安全性。方法:选择临床确诊为冠心病高危患者104例,随机分为两组:阿托伐他汀10mg.d-1组(n=50);阿托伐他汀40mg.d-1组(n=54)。分别于用药前、用药1个月、3个月、6个月时测定血清总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C),高密度脂蛋白胆固醇(HDL-C)、三酰甘油(TG)、血糖(GLU)、肝肾功能和肌酸激酶(CK),共治疗6个月。结果:(1)治疗6个月后,与治疗前相比,阿托伐他汀10mg.d-1组LDL-C、TC、TG水平分别降低38.04%、29.37%、20.74%,HDL水平升高了5.98%。40mg.d-1组LDL-C、TC、TG水平分别降低49.14%、37.69%、26.98%,HDL水平升高3.48%。10mg.d-1组LDL-C的达标率为54.00%,40mg.d-1组LDL-C的达标率为79.24%。两组间LDL-C的达标率有显著差异(P<0.01)。(2)两组间治疗前后肝肾功能和肌酸激酶等未见明显差异。结论:口服阿托伐他汀40mg.d-1较10mg.d-1治疗能更有效的降低LDL-C、TC和TG水平,使LDL-C水平达标率高,且两者的安全性一致。
Objective：To study the efficacy and safety of intensive lipid lowering with atorvastatin made in China in patients with coronary artery disease （CAD） with high risk factors. Methods： We enrolled 104 CAD patients admitted to our hospital with high risk factors. All patients were randomized to either low dose of atorvastatin group （n = 50, 10mg/daily） or large dose of atorvastatin group （n - 54, 40mg/daily） for 6 months. Total cholesterol （TC）, low density lipoprotein cholesterol （LDL-C）, high density lipoprotein cholesterol （HDL-C）, triglycerides （TG）, serum glucose, hepatic function, renal function, creatine kinase （CK） of the patients were measured before treatment and at 1 month, 3 months, 6 months, respectively. Results： After six-month treatment, LDL C, TC, TG levels were reduced by 38.04%, 29.37%, 20.74%, respectively in the low dose atorvastatin group compared with baseline; whereas reduced by 49. 14%, 37.69%, 26.98%, respectively in the high dose atorvas tatin group as compared with baseline level. As for HDL-C, it was increase of 5.98% in low dose atorvastatin group and 3.48% in high dose atorvastatin group. Responder rates were 54.00% in low dose of atorvastatin group and 79. 24% in large dose of atorvas tatin group. Much more patients in the high dose atorvastatin group achieved LDI. cholesterol goal compare with low dose atorvastatin group （P〈0. 01 ）. There were no significant difference in the hepatic function, renal function and CK between both two groups. Conclusion： Atorvastalin at 40mg/d was more powerful in decreasing LDL-C, TC and TG levels, and also more likely to achieve LDL choles terol goal compared with low dose of atorvastatin, however, safety was similar between the two groups.
出处
《中国临床医学》
北大核心
2007年第5期617-619,共3页
Chinese Journal of Clinical Medicine
基金
河北省卫生厅科研基金项目(06128)
关键词
冠心病
高危因素
阿托伐他汀
安全性
Coronary artery disease
High risk factor
Atorvastatin
Safety
